A variety of radionuclide-labeled HER2 affibody molecular probes have been successfully developed and have shown potential in preclinical experimental studies of ovarian cancer, laying a foundation for multi-center clinical trials. This evidence concerns the gene ERBB2 and ovarian carcinoma.